A 12-week, randomized, double-blind, placebo-controlled human trial of Chitooligosaccharide(GO2KA1) on decrease of body fat
- Conditions
- Endocrine, nutritional and metabolic disease
- Registration Number
- KCT0006015
- Lead Sponsor
- Wonkwang University. Iksan Korean Medicine Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 80
1) 25 = BMI = 34.9 kg/m2 or 25%(male), 30%(female) =body fat percentage
2) Participants who have fully understood information provided about the study, voluntarily decided to participate, and agreed to comply with precautions
1) Participants who have had a weight change of 10% of more within the 3 months prior to the screening examination.
2) Participants with a clinically significant disease requiring treatment (i.e., acute or chronic cardiovascular system, endocrine system, immune system, respiratory system, kidney and urinary system, neuropsychiatric system, musculoskeletal inflammation, inflammatory disease, blood and tumor disease, gastrointestinal disease, etc.)
3) Fasteners
4) Participants with a history of antipsychotic medication use within 3 months prior to the screening examination.
5) Participants who have participated in other interventional clinical trials within 3 months prior to the screening examination, or plan to participate in other interventional clinical trials.
6) Participants who are judged ineligible to participate in the trial by the principal investigator for other reasons, including laboratory test outcomes.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Fat mass by DEXA(Dual-energy X-ray absorptiometry);Percent Body Fat by DEXA(Dual-energy X-ray absorptiometry)
- Secondary Outcome Measures
Name Time Method weight;Body Mass Index(BMI)